Aktis Oncology
AKTS
114 hedge funds and large institutions have $1.1B invested in Aktis Oncology in 2026 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 6 closing their positions.
783% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 6
77% more capital invested
Capital invested by funds: $621M → $1.1B (+$480M)
65% more funds holding
Funds holding: 69 → 114 (+45)
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10.43% less ownership
Funds ownership: 74.41% → 63.98% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$14.3M |
| 2 |
BlackRock
New York
|
+$3.41M |
| 3 |
Barclays
London,
United Kingdom
|
+$2.92M |
| 4 |
Renaissance Technologies
New York
|
+$1.96M |
| 5 |
Polen Capital Management
Boca Raton,
Florida
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.2M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.88M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.68M |
AKTS Hedge Fund Activity: Q2 2026 in Review
114 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Aktis Oncology (AKTS) for Q2 2026, worth a combined $1.1B — up 77% from $621M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new AKTS positions and 6 closed out — a net gain of 47 holders — while 28 added to existing stakes and 17 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $14.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $16.4M.
- 114 institutional investors held Aktis Oncology (AKTS) as of Q2 2026, up from 69 in Q1 2026.
- Funds reported $1.1B of Aktis Oncology stock for Q2 2026, up 77% quarter-over-quarter.
- 53 funds opened new Aktis Oncology positions in Q2 2026 and 6 closed out, a net change of +47 holders.
- The largest Aktis Oncology buyer in Q2 2026 was TCG Crossover Management, an estimated $14.3M added.
- The largest Aktis Oncology seller in Q2 2026 was T. Rowe Price Associates, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2026.